Atlas Trials

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Clinical trial NCT03391466 · COMPLETED

Trial details

NCT number
NCT03391466
Sponsor
Kite, A Gilead Company
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Start date
2018-01-25
Primary completion
2021-03-18
Enrollment
359

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.